Abstract
The XVIVO Heart Box (XHB) is an emerging technology in cardiac transplantation that protects the donor heart via non-ischaemic heart preservation (NIHP). A first-in-human trial utilising XHB demonstrated its safe use in human cardiac transplantation [ [1] Nilsson J, Jernryd V, Qin G, Paskevicius A, Metzsch C, Sjöberg T, et al. A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation. Nat Commun. 2020;11:2976. Google Scholar ]. In response, an Australian and New Zealand multicentre trial of extended (6–8 hours) NIHP of donor hearts for transplantation utilising XHB is underway. The current study is an open-labelled, single-arm, multicentre clinical trial. It aims to investigate the effect of NIHP on donor hearts with extended ischaemic time (6–8 hours) with respect to immediate and long-term post-transplant heart allograft function.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
